News

The FDA clearance allows the company to start expanding its clinical investigation of PROHEMA into rare, non-malignant disorders. The company intends to start enrollment of the Phase Ib

Tanzeum is a once weekly option for patients, in combination with some other glucose-lowering medicines. In April 2014, the drug was approved by the US Food and Drug

Sunshine Biopharma anticipates that Sunshine Biopharma Canada will soon sign manufacturing, marketing, sales and distribution contracts for various pharmaceutical and biomedical products. According to various estimates, the worldwide

This operation, which will be realized in the coming weeks subject to the completion of certain usual conditions, is for Cellectis the extension to its strategic therapeutic focus.

Research shows that cannabinoids have medical application for a range of conditions as varied as epilepsy, glaucoma, osteoporosis, anorexia, Alzheimer’s disease and pain treatment. Following the recent success

U.S. Patent No. 8,765,928 entitled "Identification of isolated genomic nucleotide fragments from the p15 region of chromosome 11 encoding human tumor suppressing subtransferable candidate 4 (TSSC4) and variants

The company’s new development direction includes large molecule drugs that will address indications in diabetes and the overall metabolic syndrome. The company’s sub-micron technology allows for development of

Three months after its authorization by the ANSM, the French authority for drug safety, a first patient has been enrolled. Having already successfully completed a Phase I study

Gazyvaro, a new, type II, glycoengineered monoclonal antibody, is marketed as Gazyva outside of the EU and Switzerland. It is designed to attach to CD20, a protein found